Read Aloud the Text Content

This audio was created by Woord's Text to Speech service by content creators from all around the world.

Text Content or SSML code:

Good morning, my name is Youssef Ahmiane, I am doing my doctoral thesis at the University Rovira i Virgili directed by Javier CAPILLA and Marta SANCHIS as my directors. Today I am going to present in this Conference/talk our work titled: "In vitro activity and in vivo efficacy of flavone F46 alone or in combination with azoles against Candida auris". in collaboration with a research group from the University of Graz. Introduction: Fist of all, Fungi are heterotrophic eukaryotic organisms belonging to the kingdom Fungi. Fungi have two different modes of living. The majority of fungi live as filamentous fungi and are multicellular organisms. Fungi can also live as free unicellular organisms, better known as yeasts. But these are only modes of living. Some fungi are dimorphic because they can go from being unicellular to multicellular depending on environmental conditions. Fungi have a cell wall rich in chitin and a membrane rich in ergosterol which It is direct or indirect target of most antifungals. Although most fungal species are saprophytes, there are species that are pathogenic to plants and animals (including humans). Infections caused by fungi are called mycoses and are classified according to the tissue that is infected such as mycoses superficial, subcutaneous, deep or systemic in which two or more non-contiguous organs or an organ and blood. The most frequent infections are caused by Candida albicans and Aspergillus fumigatus in the population with immunodeficiency due to chemotherapy, transplantation or AIDS. Furthermore, diabetes or antibiotic use are risk factors for acquiring mycoses. These infections represent a major problem due to the difficulty of diagnosis (although it has been improved with the introduction of molecular identification techniques), resistance to different drugs on the interim market or by acquisition. And finally, underlying diseases make the treatment of patients very difficult. These infections represent a major problem due to the difficulty of diagnosis (although it has been improved with the introduction of molecular identification techniques), resistance to different drugs, both intrinsic and acquired. And finally, underlying diseases make treating patients very difficult. One of the emerging fungi today has been Candida auris which is a yeast first described in 2009, Japan, and has spread rapidly around the world as shown on the map (more than 30 countries on six continents). In Spain there was an outbreak of Candida auris at the Hospital General Universitario of Valencia in 2017. Candida auris represents a public health problem because it is often multi-resistant to different drugs available on the market. Moreover, It can produce nosocomial infections and has ability to persist, both on the human host and also at environment by biofilm formation. Over the last decades, the increase of invasive fungal infections and the emergence of multiresistant clinical isolates are making necessary new therapeutic approaches. In this sense, the development of new drugs, the administration of combined treatments, and the incorporation of natural compounds are current strategies in in the antifungal pipeline or approach Natural compounds such as phenolic compounds are a large group of molecules, that include flavones which are a subgroup of flavonoids, can be an excellent alternative therapy to reducing side effects and toxicity shown by conventional antifungal treatments. In addition to their interesting antioxidant, anti-inflammatory, antibiofilm and, antimicrobial and other activities. ------ Previous studies showed an excellent antifungal and antibiofilm activity of flavones or flavonoids against invasive candidiasis by different Candida species